Annovis Bio, Inc.
ANVS
|
$10.09
2.44%
-0.15%
220K
|
Health Technology
(0.0% 1d) (-15.0% 1m) (-36.4% 1y) (2.1% 2d) (2.1% 3d) (-9.3% 7d) (-6.96% volume)
Earnings Calendar:
Market Cap: $ 111,104,007
http://www.annovisbio.com
Sec Filling | Patents | 2 employees
(US) Annovis Bio, Inc. develops drugs for Alzheimer's and Parkinson's diseases and other neurodegenerative disorders. It offers posiphen compound for mild cognitive impairment and early stage Alzheimer's disease and bisnorcymserine compound that inhibits amyloid formation and prevents the progression of the Alzheimer's disease. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Berwyn, PA.
neurodegenerative alzheimer parkinson alzheimer’s
add to watch list Paper trade email alert is off
Press-releases
Annovis Announces Publication That Supports Understanding of Buntanetap’s Mechanism of Action in Humans
Published: 2024-04-01 (Crawled : 12:00) - globenewswire.com
ANVS | $10.09 2.44% -0.15% 220K
|
Health Technology
|
| O: -0.66%
H: 3.67%
C: -0.33%
publication
Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s Disease
Published: 2024-03-20 (Crawled : 12:00) - biospace.com/
ANVS | $10.09 2.44% -0.15% 220K
|
Health Technology
|
| O: 10.43%
H: 34.62%
C: 12.69%
announcement disease alzheimer’s update buntanetap study
Annovis Bio Announces Participation in Forum Discussion at AD/PD™ 2024
Published: 2024-02-27 (Crawled : 13:00) - globenewswire.com
ANVS | $10.09 2.44% -0.15% 220K
|
Health Technology
|
| O: -0.68%
H: 12.15%
C: 11.12%
Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer’s Disease
Published: 2024-02-14 (Crawled : 13:00) - biospace.com/
ANVS | $10.09 2.44% -0.15% 220K
|
Health Technology
|
| O: 2.99%
H: 2.51%
C: 0.19%
disease alzheimer’s buntanetap study
Annovis Bio Announces the Filing of New Patent Application for Treatment of Mental Illnesses Expanding the Company’s Portfolio
Published: 2024-01-30 (Crawled : 13:00) - globenewswire.com
ANVS | $10.09 2.44% -0.15% 220K
|
Health Technology
|
| O: 5.45%
H: 0.0%
C: -10.42%
patent treatment application
Annovis Bio Refines Timeline for Parkinson’s Phase III Study Data Announcement
Published: 2024-01-24 (Crawled : 13:00) - globenewswire.com
ANVS | $10.09 2.44% -0.15% 220K
|
Health Technology
|
| O: -10.18%
H: 0.0%
C: -13.06%
announcement parkinson’s study
Annovis Bio to Participate in the 139th Yale CEO Summit
Published: 2023-12-11 (Crawled : 18:00) - globenewswire.com
ANVS | $10.09 2.44% -0.15% 220K
|
Health Technology
|
| O: 2.35%
H: 1.04%
C: -4.38%
ceo
Annovis Bio Announces Last Patient Last Visit in the Phase III Study of Buntanetap in Parkinson’s Disease
Published: 2023-12-05 (Crawled : 12:30) - globenewswire.com
ANVS | $10.09 2.44% -0.15% 220K
|
Health Technology
|
| O: 1.52%
H: 11.4%
C: 3.0%
disease buntanetap parkinson’s study
Annovis Bio Appoints Andrew Walsh as Vice President Finance
Published: 2023-12-01 (Crawled : 17:00) - globenewswire.com
ANVS | $10.09 2.44% -0.15% 220K
|
Health Technology
|
| O: 2.47%
H: 3.45%
C: -2.41%
Annovis Bio Announces Full Enrollment of Its Phase II/III Alzheimer’s Disease Trial, Exceeding Original Projections
Published: 2023-11-27 (Crawled : 12:30) - globenewswire.com
ANVS | $10.09 2.44% -0.15% 220K
|
Health Technology
|
| O: 4.62%
H: 17.65%
C: 8.68%
disease alzheimer’s
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 67% | 33% |
Top 10 Gainers
Last 48 Hours Insiders Buying
RXO P 200000 | $19.37 2.32% 0.0% 1M
|
n/a
|
23:00
RKT P 380 | $11.68 1.3% 0.17% 1.9M
|
Finance
|
22:30
HROW P 29400 | $10.43 -3.87% -4.03% 680K
|
Health Technology
|
22:30
BCDA P 2750 | $0.377 -1.4% 97K
|
Health Technology
|
22:00
RMCF | $3.67 3.38% 3.27% 11K
|
Consumer Non-Durables
|
20:10